Loading...
OTCM
CYDY
Market cap296mUSD
Oct 08, Last price  
0.20USD
1D
0.80%
1Q
-13.89%
Jan 2017
-69.93%
IPO
-90.40%
Name

Cytodyn Inc

Chart & performance

D1W1MN
OTCM:CYDY chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
17.02%
Rev. gr., 5y
%
Revenues
0
P
00005,7860000000000266,00000-5,916,0000
Net income
-43m
L
-2,610,000-1,194,000-1,573,000-3,737,000-3,741,000-7,493,000-9,568,000-12,431,000-25,088,000-25,704,000-25,764,000-50,150,000-56,187,000-139,936,000-174,018,000-210,820,000-79,824,000-49,841,0003,745,000-42,699,000
CFO
-17m
L+96.83%
-935,090-473,308-1,287,005-2,146,410-1,821,417-4,391,095-3,392,933-7,386,943-12,016,858-24,810,651-26,732,468-29,897,971-50,466,164-68,803,615-117,573,000-77,723,000-25,110,000-10,982,000-8,765,000-17,252,000
Earnings
Oct 09, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.

Key people

Tanya Urbach
Independent Chairman of the Board · since 2022
Jacob Lalezari
Chief Executive Officer · since 2024
Mitchell Cohen
Interim Chief Financial Officer · since 2024
Robert Hoffman
Chief Financial Officer · since 2025
Max Lataillade
Senior Vice President and Head of Clinical Development · since 2024
Tyler Blok
Corporate Secretary, Chief Legal Officer · since 2024
Karen Brunke
Independent Director · since 2022
Ryan Dunlap
Independent Director · since 2022
Lishomwa Ndhlovu
Independent Director · since 2021
Stephen Simes
Independent Director · since 2022
URL
https://www.cytodyn.com/
IPO date
Nov 17, 2005
Employees
23
Domiciled in
US
Incorporated in
US
Headquarters & legal address
c/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑052025‑052024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑05
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT